

Form PTO-1449 (modified)

JUL 30 2002

Atty. Docket No.

UTSC:664US

Serial No.

09/599,152

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616

AUG 01 2002

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
20	A1	5,108,921	04/28/92	Low <i>et al.</i>	435	240.1	03/28/90
	A2	5,279,811	1/18/94	Bergstein <i>et al.</i>	424	1.1	1/26/88
	A3	5,416,016	05/16/95	Low <i>et al.</i>	435	240.1	03/13/92
	A4	5,635,382	06/03/97	Low <i>et al.</i>	435	172.3	12/05/94
	A5	5,688,488	11/18/97	Low <i>et al.</i>	424	1.69	05/16/95
	A6	5,730,968	3/24/98	Butterfield <i>et al.</i>	424	78.37	3/31/94
	A7	5,820,847	10/13/98	Low <i>et al.</i>	424	9.1	01/15/97
	A8	5,951,964	9/14/99	Dean <i>et al.</i>	424	1.69	6/4/93
	A9	5,955,053	9/21/99	Marzilli <i>et al.</i>	424	1.11	5/6/96
	A10	5,977,163	11/2/99	Li <i>et al.</i>	514	449	3/11/97
	A11	5,986,074	11/16/99	Marzilli <i>et al.</i>	534	14	12/18/97
	A12	6,197,278	3/6/01	Blankenberg <i>et al.</i>	424	1.69	4/29/98

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
20	C37	Alper <i>et al.</i> , "Assessment of renal functional changes following transurethral prostatectomy using tc-99m ethylenedicycysteine," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1292, 1996.
20	C38	Anderson <i>et al.</i> , "N,N'-ethylene-di-l-cysteine (ec) complexes of ga(III) and In (III): molecular modeling, thermodynamic stability and in vivo studies," <i>Nucl. Med. Biol.</i> , 22:165-173, 1995.

Examiner:

DATE CONSIDERED:

10/25/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications of Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
UTSC:664USSerial No.
09/599,152Applicant
David Yang *et al.*Filing Date:
June 21, 2000Group:
1616U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
79	C39	Baidoo and Lever, "Evaluation of a diaminedithiol-based bifunctional chelate for labeling small molecules with ^{99m} Tc," <i>Technetium and Rhenium in Chemistry and Nuclear Medicine</i> , 1990.
	C40	Baidoo <i>et al.</i> , "Synthesis of a new diaminedithiol bifunctional chelate for the preparation of neutral technetium complexes," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 414, 1990.
	C41	Bar-Sever <i>et al.</i> , "Comparison of living related donor and recipient renograms in predicting the early postransplantation course," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1305, 1996.
	C42	Bush <i>et al.</i> , "Definitive evidence for hypoxic cells influencing cure in cancer therapy," <i>Br J Cancer</i> , (Suppl. III) 37:302-306, 1978.
	C43	Campbell <i>et al.</i> , "Folate-binding protein is a marker for ovarian cancer," <i>Cancer Res</i> , 51:5329-5338, 1991.
	C44	Chen <i>et al.</i> , "Biological and pharmacokinetic evaluation of tc-99m ma2g2-b: a potential renal agent," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1082, 1994.
	C45	Cherif <i>et al.</i> , "Rapid synthesis of [¹⁸ F]Fluoro-1-(2'-Nitro-1'-Imidazolyl)-2-Propanol ([¹⁸ F]Fluoromisonidazole)," <i>Pharm Res.</i> , 11:466-469, 1994.
	C46	Cleynhens <i>et al.</i> , "Synthesis and biological evaluation in mice of a monoamide derivative of tc-99m-1,1-ec," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 799, 1997.
	C47	Coney <i>et al.</i> , "Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing," <i>Cancer Res</i> , 54:2448-2455, 1994.
	C48	Corlija <i>et al.</i> , "Contribution of radiolytically induced dissociation of 99mtc-d,1-hmpao in aqueous solutions," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 413, 1990.
	C49	Craig <i>et al.</i> , "Renal outcomes for children on year after urinary tract infection," <i>J. Nuclear Med.</i> , 37:46P, Abstract No. 175, 1996.
	C50	Dagli <i>et al.</i> , "Analysis of the complete dynamic scan data for camera-based determination of renal function," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 354, 1996.
79	C51	de Klerk <i>et al.</i> , "Aspirin versus captopril renography in the diagnosis of renal artery stenosis," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1291, 1996.

Examiner

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications of Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSC:664US

Serial No.

09/599,152

Applicant

David Yang *et al.*

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
DF	C52	Dewanjee <i>et al.</i> , "Labeling antisense oligodeoxynucleotide (on) with tc-99m and hybridization with c-myc oncogene mrna in p388 leukemic cells," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1081, 1994.
	C53	Dezutter <i>et al.</i> , "Preparation and biological evaluation of technetium- ^{99m} -L,L-propylenedicysteine" <i>J. of Labelled Cpd. Radiopharm.</i> , 42:553-565, 1999.
	C54	Dische, "A review of hypoxic-cell radiosensitization," <i>Int J Radiat Oncol Biol Phys</i> , 20:147-152, 1991.
	C55	Eisenhut <i>et al.</i> , "Synthesis and <i>In Vivo</i> Testing of a bromobutyl substituted 1,2-Dithia-5,9-diazacycloundecane: a versatile precursor for new ^{99m} Tc-bis(aminoethanethiol) complexes," <i>Nucl. Med. Biol.</i> , 16:805-811, 1989.
	C56	Eshima <i>et al.</i> , "Evaluating the role of protein binding on the renal extraction of tc-99m tubular agents utilizing an isolated perfused rat kidney model," <i>J. Nuclear Med.</i> , 37:47P, Abstract No. 178, 1996.
	C57	Fanciulli <i>et al.</i> , "Glycolysis and growth rate in normal and in hexokinase-transfected NIH-3T3 cells," <i>Oncology Res.</i> , 6:405-409, 1994.
	C58	Franklin <i>et al.</i> , "New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma," <i>Int J Cancer-Supplement</i> , 8:89-95, 1994.
	C59	Giraud <i>et al.</i> , "Application to a cartilage targeting strategy: Synthesis and in vivo biodistribution of ¹⁴ C-labelled quaternary ammonium-glucosamine conjugates," <i>Bioconjug. Chem.</i> , 11:212-218, 2000.
	C60	Goh <i>et al.</i> , "Growth hormone promotion of tubulin polymerization stabilizes the microtubule network and protects against colchicine-induced apoptosis," <i>Endocrinology</i> , 139:4364-4372, 1998.
	C61	Guozheng and Boli, "A new potential renal imaging agent ^{99m} Tc-n-ec," <i>J. Labelled compounds and Radiopharmaceuticals</i> , XXXVII:797-798, 1995.
DF	C62	Harada <i>et al.</i> , "Insulin-induced egr-1 expression in chinese hamster ovary cells in insulin receptor an insulin receptor substrate-1 phosphorylation-independent," <i>J. Biol Chem.</i> , 270:26632-26638, 1995.

Examiner:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications of Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
UTSC:664USSerial No.
09/599,152Applicant
David Yang *et al.*Filing Date:
June 21, 2000Group:
1616

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C63	Hay <i>et al.</i> , "Hypoxia-selective antitumor agents. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers," <i>J Med. Chem.</i> , 37:381-391, 1994.
	C64	Hermann and Patel, "Adaptive recognition by nucleic acid aptamers," <i>Science</i> , 287:820-825, 2000.
	C65	Holm <i>et al.</i> , "Folate receptor of human mammary adenocarcinoma," <i>APMIS</i> , 102:413-419, 1994.
	C66	Hsueh and Dolnick, "Altered folate-binding protein mRNA stability in KB cells grown in folate-deficient medium," <i>Biochem Pharmacol</i> , 45:2537-2545, 1993.
	C67	Ilgan <i>et al.</i> , " ^{99m} Tc-ethylenedicysteine-folate: a new tumor imaging agent, synthesis, labeling and evaluation in animals," <i>Cancer Biotherapy & Radiopharmaceuticals</i> , 13:427-435, 1998.
	C68	Itoh <i>et al.</i> , "Graphic (patlak) method in tc-99m-mag3 renal scintigraphy: noninvasive calculation of extraction fraction (ef) and renal plasma flow (RPF)," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1300, 1996.
	C69	John <i>et al.</i> , "Tc-99m labeled ethylenediamines: quest for sigma receptor chelates," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 798, 1997.
	C70	Jones and Mayer, "Glucose metabolism in the rat small intestine: the effect of glucose analogues on hexokinase activity," <i>Biochem. J</i> , 132:125-128, 1973.
	C71	Kabasakal <i>et al.</i> , "Clinical comparison of technetium- ^{99m} -ec, technetium- ^{99m} -MAG3 and iodine-131-OIH in renal disorders," <i>J. Nucl. Med.</i> , 36(2):224-228, 1995.
	C72	Kabasakal <i>et al.</i> , "Evaluation of technetium-99m-ethylenedicysteine in renal disorders and determination of extraction ratio," <i>J. Nucl. Med.</i> , 36(8):1398-1403, 1995.
	C73	Kabasakal <i>et al.</i> , "Prospective validation of single plasma sample ^{99m} Tc-ethylenedicysteine clearance in adults," <i>J. Nucl. Med.</i> , 40:429-431, 1999.
	C74	Kabasakal <i>et al.</i> , "Simplified technetium- ^{99m} -EC clearance in adults from a single plasma sample," <i>J. Nuclear Med.</i> , 38:1784-1786, 1997.
	C75	Kanvinde <i>et al.</i> , "Technetium-99m-γ-pyrones: a new class of tc-99m cationic complexes," <i>J. Nuclear Medicine</i> , 31:908, Abstract, 1990.

Examiner:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)




List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
UTSC:664USSerial No.
09/599,152Applicant
David Yang *et al.*Filing Date:
June 21, 2000Group:
1616U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C76	Kao <i>et al.</i> , "Role of radioisotope penile plethysmigraphy in the evaluation of penile hemodynamic of impotent patients," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1304, 1996.
	C77	Kengen, "Good results of tc-99m-mag3 clearance measurements with a dual headed gamma camera without plasma sampler," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 353, 1996.
	C78	Kikukawa <i>et al.</i> , "Early and delayed Tc-99m ECD brain SPECT in SLE patients with CNS involvement," <i>Ann Nucl Med.</i> 14:25-32, 2000.
	C79	Kim <i>et al.</i> , "Synthesis, biodistribution and imaging of mammary tumors using 99mtc-ec-polyglutamate; a glutamate receptor peptide," <i>J. Nuclear Medicine</i> , 41:231P Abstract, 2000.
	C80	Kranz <i>et al.</i> , "Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis," <i>Proc Natl Acad Sci</i> , 92:9057-9061, 1995.
	C81	Lamberts <i>et al.</i> , "Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog," <i>J. Steroid Biochem Mol Biol</i> , 37:1079-1082, 1990.
	C82	Leamon and Low, "Cytotoxicity of momordin-folate conjugates in cultured human cells," <i>J Biol Chem</i> , 267:24966-24971, 1992.
	C83	Leamon <i>et al.</i> , "Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells," <i>J Biol Chem</i> , 268:24847-24854, 1993.
	C84	Lee and Low, "Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis," <i>J Biol Chem</i> , 269:3198-3204, 1994.
	C85	Liang <i>et al.</i> , "The use of diaminodithiol for labeling small molecules with technetium-99m," <i>Nucl. Med. Biol.</i> , 14:63-67, 1987.
	C86	Lu, "Antimitotic agents," In: Foye, WO. Ed., "Cancer chemotherapeutic agents," Washington, DC: American Chemical Society, 345-368, 1995.
	C87	Mang'era and Verbruggen, "Synthesis and evaluation of beta-homocysteine derivatives of 99mtc-1,1-ec and 99mtc-1,1-ecd," <i>J. of Labelled Compounds and Radiopharmaceuticals</i> , 42:683-699, 1999.
	C88	Mason <i>et al.</i> , "99mtc-desferoxamine: production, stability and solute clearance measurements after aerosolization," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 865, 1990.

Examiner:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
UTSC:664USSerial No.
09/599,152Applicant
David Yang *et al.*Filing Date:
June 21, 2000Group:
1616U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C89	Mather <i>et al.</i> , "Tumour cell uptake of technetium dithiocarbamate complexes," <i>J. Nuclear Med.</i> , 38:186P, Abstract No. 797, 1997.
	C90	Mease <i>et al.</i> , "Comparison of renal agents for detecting unilateral acute ischemic/reperfusion renal injury in rats," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1033, 1995.
	C91	Michiels <i>et al.</i> , "Simultaneous estimation of effective renal plasma flow and glomerular filtration rate using tc-99m-ec," <i>J. Nuclear Med.</i> , 37:91P, Abstract No. 355, 1996.
	C92	Mochizuki <i>et al.</i> , "Synthesis of poly-L-glutamates containing 5-substituted uracil moieties," <i>Nucleic Acids Symp. Ser.</i> , 16:121-124, 1985.
	C93	Moller <i>et al.</i> , "Biologic activities of naturally occurring human insulin receptor mutations," <i>J. Biol. Chem.</i> , 266:10995-11001, 1991.
	C94	Moran, "Technetium- ^{99m} -EC and other potential new agents in renal nuclear medicine," <i>Seminars in Nucl. Med.</i> , 29: 91-101, 1999.
	C95	Morton <i>et al.</i> , "Comparison of 2-point postural drainage with diuresis renography in the assessment hydronephrosis," <i>J. Nuclear Med.</i> , 37:46P, Abstract No. 174, 1996.
	C96	Mrhac <i>et al.</i> , "Abnormal first-pass flow through the azygos vein from valsalva maneuver," <i>Clinical Nucl. Med.</i> , 21:331-332, 1996.
	C97	Nosco <i>et al.</i> , "Development of a kit formulation for 99mtcmag3 of very high purity and very high stability," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 863, 1990.
	C98	Offield <i>et al.</i> , "PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum," <i>Development</i> , 122:983-995, 1996.
	C99	Orr <i>et al.</i> , "Similarity of folate receptor expression in UMSCC 38 cells to squamous cell carcinoma differentiation markers," <i>J Natl Cancer Inst</i> , 87:299-303, 1995.
	C100	Ozker <i>et al.</i> , "Technetium- ^{99m} -N,N-ethylenedicysteine-a comparative study of renal scintigraphy with technetium- ^{99m} -MAG3 and iodine-131-OIH in patients with obstructive renal disease," <i>J. Nucl. Med.</i> , 35:840-845, 1994.
	C101	Piper <i>et al.</i> , "A synthetic approach to poly(γ -glutamyl) conjugates of methotrexate," <i>J. Med. Chem.</i> , 26:291-294, 1983.

Examiner:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSC:664US

Serial No.

09/599,152

Applicant

David Yang *et al.*

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)


Exam. Init.	Ref. Des.	Citation
20	C102	Pirmettis <i>et al.</i> , "Synthesis and characterization of the tcd(ec) complex, a renal imaging agent," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1079, 1994.
	C103	Popovici <i>et al.</i> , "The influence of some antibiotics on hexokinase and pyruvate-kinase activity in the rat liver and kidney," <i>Arch. int. Pharmacodyn.</i> , 193:80-86, 1971.
	C104	Prvulovich <i>et al.</i> , "Clinical evaluation of technetium- ^{99m} -L,L-ethylenedicycysteine in patients with chronic renal failure," <i>J. Nucl. Med.</i> , 38:809-814, 1997.
	C105	Raffauf <i>et al.</i> , "Colchicine. Derivatives of trimethylcolchicinic acid," <i>J. Am Chem Soc.</i> , 75:5292-5294, 1953.
	C106	Ratner and Clarke, "The action of formaldehyde upon cysteine," <i>J. Am Chem. Soc.</i> , 59:200-206, 1937.
	C107	Rogers <i>et al.</i> , "Neomycin effects on glucose transport by rat small intestine," <i>Digestion</i> , 1:159-164, 1968.
	C108	Ross <i>et al.</i> , "Differential regulation of folate receptor isoforms in normal and malignant tissue in vivo and in established cell lines," <i>Cancer</i> , 73:2432-2443, 1994.
	C109	Sasaki <i>et al.</i> , "Assessment of antioxidative ability in brain: imaging of glutathione localization with technetium-99m meso-hexamethyl propyleneamine," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1083, 1994.
	C110	Sato <i>et al.</i> , "Simple estimation of fractional renal uptake of tc-99m mag3 using graphical analysis without syringe counting and renal depth correction," <i>J. Nuclear Med.</i> , 37:292P, Abstract No. 1303, 1996.
	C111	Shankar <i>et al.</i> , "Glucosamine infusion in rats mimics the beta-cell dysfunction of non-insulin-dependent diabetes mellitus," <i>Metabolism</i> , 47:573-577, 1998.
20	C112	Shattuck <i>et al.</i> , "Validation of the two sample technique for measuring gfr in renal transplant patients," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1036, 1995.
20	C113	Shuke <i>et al.</i> , "Modified renal counting method for estimation of tc-99m mag3 renal clearance," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1301, 1996.

Examiner:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

Atty. Docket No.
UTSC:664USSerial No.
09/599,152

List of Patents and Publications for Applicant's

Applicant
David Yang *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
June 21, 2000Group:
1616

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 2

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C114	Stoffel <i>et al.</i> , "Evaluation of technetium-99m-L,1-ec in renal transplant recipients: a comparative study with technetium- ^{99m} -MAG3 and iodine-125-OIH, <i>J. Nucl. Med.</i> , 35:1951-1958, 1994.
	C115	Subramanian <i>et al.</i> , "Transchelation reactions in labeling ecd with tc-99m," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 867, 1990.
	C116	Suzuki <i>et al.</i> , "A modified graphic method for estimation of glomerular filtration index using dynamic renal images with tc-99m dtpa," <i>J. Nuclear Med.</i> , 36:231P, Abstract No. 1035, 1995.
	C117	Tait and Smith, "Site-specific mutagenesis of annexin V: role of residues from Arg-200 to Lys-207 in phospholipid binding," <i>Arch Biochem Biophys</i> , 288:141-144, 1991.
	C118	Taylor <i>et al.</i> , "Comparison of tc-99m0(n,n1-ethylenedicysteine isomers in rats and in normal volunteers," <i>J. Nuclear Med.</i> , 37:46P-47P, Abstract No. 177, 1996.
	C119	Taylor <i>et al.</i> , "Comparison of technetium- ^{99m} -LL-EC isomers in rats and humans," <i>J. Nucl. Med.</i> , 38:821-826, 1997.
	C120	Tsukamoto <i>et al.</i> , "The quantitation of absolute tc-99m-dmsa renal uptake in children from planar posterior-view method," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1299, 1996.
	C121	Tuli <i>et al.</i> , "Comparison of a simplified quantitation of tc-99m mag-3 renogram to core needle biopsy in the diagnosis of renal transplant rejection," <i>J. Nuclear Med.</i> , 37:289P, Abstract No. 1290, 1996.
	C122	Ugar <i>et al.</i> , "The diagnosis of renovascular hypertension with technetium-99m-ethylenedicysteine captopril scintigraphy," <i>Investigative Radiology</i> , 31:497-501, 1996.
	C123	Ugur <i>et al.</i> , "Renovascular hypertension due to takayasu's arteritis demonstrated by Tc- ^{99m} ethylenedicysteine captopril scintigraphy," <i>Clinical Nuclear Medicine</i> , 21:714-716, 1996.
	C124	Ugur <i>et al.</i> , "Technetium- ^{99m} -ethylenedicysteine in the diagnosis and follow-up of renovascular hypertension," <i>Investigative Radiology</i> , 31:378-381, 1996.
	C125	Ugur <i>et al.</i> , "Technetium- ^{99m} -ethylenedicysteine: an alternative agent to detect renovascular hypertension," <i>J. of Nuclear Med.</i> , 38:1662-1664, 1997.
	C126	Ugur <i>et al.</i> , "The diagnosis of renovascular hypertension with tc-99m ethylenedicysteine captopril scintigraphy," <i>J. Nuclear Med.</i> , 37:291P, Abstract No. 1302, 1996.

Examiner:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP605; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

JUL 30 2002

Atty. Docket No.

UTSC:664US

Serial No.

09/599,152

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C127	Van Nerom <i>et al.</i> , "Comparison of renal excretion ocharacteristics of isomers l,l and d,d of tc-99m ethylenedicysteine," <i>J. Nuclear Med.</i> , 31:806, Abstract No. 412, 1990.
	C128	Van Nerom <i>et al.</i> , "Optimalization of the labelling of ethylenedicysteine (ec) with technetium-99m," <i>J. Labelled Compounds and Radiopharmaceuticals</i> , XXX:37-39, 1991.
	C129	Van Schepdael <i>et al.</i> , "Capillary electrophoretic analysis of ethylene dicysteine, a precursor of the radiopharmaceutical ^{99m} Tc ethylene dicysteine," <i>J. Chromatography B</i> , 697:251-254, 1997.
	C130	Verbruggen <i>et al.</i> , "Is syn or anti orientation of the oxotechnetium and carboxyl group in tc-99m renal function agents affecting the renal excretion rate?" <i>J. Labelled Compounds and Radiopharmaceuticals</i> , XXX:86-88, 1991.
	C131	Verbruggen <i>et al.</i> , "Tc-99m l,l-ethylenedicysteine, a potential alternative to tc-99m mag3," <i>J. Nuclear Med.</i> , 31:908, Abstract No. 864, 1990.
	C132	Villevalois-Cam <i>et al.</i> , "Insulin-induced redistribution of the insulin-like growth factor II/mannose 6-phosphate receptor in intact rat liver," <i>J. Cell. Biochem.</i> , 77:310-322, 2000.
	C133	Washburn <i>et al.</i> , "Reliable kit preparation of tc99m pentavalent dimercaptosuccinic acid [tc-99m (v) dmsa]," <i>J. Nuclear Med.</i> , 35:263P, Abstract No. 1080, 1994.
	C134	Weitman <i>et al.</i> , "Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis," <i>Cancer Res</i> , 52:6708-6711, 1992b.
	C135	Weitman <i>et al.</i> , "The folate receptor in central nervous system malignancies of childhood," <i>J Neuro-Oncology</i> , 21:107-112, 1994.
	C136	Weitman <i>et al.</i> , "Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues," <i>Cancer Research</i> , 52:3396-3401, 1992.
	C137	Westerhof <i>et al.</i> , "Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: Role of carrier- and receptor- mediated transport systems," <i>Cancer Res</i> , 51:5507-5513, 1991.
V	C138	Yang <i>et al.</i> , "99mtc-ec-deoxyglucose: synthesis, cellular uptake, biodistribution an dscintigraphic imaging," <i>J. Labelled Cpd. Radiopharm.</i> , 44:S513-S514, Abstract, 2001.
W	C139	Yang <i>et al.</i> , "Imaging tumor folate receptors using 99mtc-ethylenedicysteine-folate," <i>Proceedings of the American Association for Cancer Research</i> , 40:259, Abstract #1720, 1999.

Examiner:

DATE CONSIDERED:

10/25/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

JUL 30 2002

Atty. Docket No.
UTSC:664USSerial No.
09/599,152

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
David Yang *et al.*Filing Date:
June 21, 2000Group:
1616U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C140	Yang <i>et al.</i> , "Imaging tumor folate receptors using radiolabeled folate and methotrexate," <i>J. Labelled Cpd. Radiopharm.</i> , 42:S696-S697, 1999.
	C141	Yang <i>et al.</i> , "Molecular imaging using 99m-tc-ec-nitroimidazole, and 99mtc-ec-annexin v in tumor-bearing rodents," <i>Proceedings for the American Association for Cancer Research Annual Meeting</i> , 41:766, Abstract, 2000.
	C142	Yang <i>et al.</i> , "Noninvasive assessment of tumor hypoxia with ^{99m} Tc labeled metronidazole," <i>Pharmaceutical Research</i> , 15:743-750, 1999.
	C143	Yoshino <i>et al.</i> , "Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats," <i>Metabolism</i> . 48:1418-23, 1999.
	C144	Zakko <i>et al.</i> , "Biliary excretion of Tc- ^{99m} ec in renal studies," <i>Clinical Nuclear Medicine</i> , 23:417-419, 1998.
	C145	Zareneyrizi <i>et al.</i> , "Synthesis of [^{99m} Tc] ethylenedicysteine-colchicine for evaluation of antiangiogenic effect," <i>Anti-Cancer Drugs</i> , 10:685-692, 1999.

Examiner:

DATE CONSIDERED:

10/25/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)